ITI AB1
Alternative Names: ITI-AB1Latest Information Update: 02 Mar 2021
At a glance
- Originator Immunomic Therapeutics
- Class Cancer vaccines; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Mar 2021 Preclinical trials in Cancer in USA (Parenteral) before March 2021 (HLB pipeline, March 2021)